Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis

摘要

Background New first-line drug regimens for treatment of tuberculosis (TB) are in clinical trials: emergence of resistance is a key concern. Because population-level data on resistance cannot be collected in advance, epidemiological models are important tools for understanding the drivers and dynamics of resistance before novel drug regimens are launched.